{"id":"molsidomine","rwe":[{"pmid":"41480767","year":"2026","title":"Nitric oxide required for transition to slower hepatic protein synthesis rates during long-term caloric restriction.","finding":"","journal":"The Journal of clinical investigation","studyType":"Clinical Study"},{"pmid":"41273551","year":"2026","title":"Exploring Therapeutic and Multitarget Mechanism of Molsidomine on Cerebral Ischemia: Molecular Docking and Multifaceted In Silico Study.","finding":"","journal":"Advances in experimental medicine and biology","studyType":"Clinical Study"},{"pmid":"40490173","year":"2025","title":"Molsidomine ameliorates DEXA-induced insulin resistance: Involvement of HMGB1/JAK1/STAT3 signaling pathway.","finding":"","journal":"European journal of pharmacology","studyType":"Clinical Study"},{"pmid":"40453484","year":"2025","title":"Comparative analysis of two standardised protocols for prevention of vasospasm following aneurysmal subarachnoid haemorrhage: A retrospective pilot study.","finding":"","journal":"European journal of anaesthesiology and intensive care","studyType":"Clinical Study"},{"pmid":"40251020","year":"2025","title":"Corrigendum: Evaluation of the potential efficacy of the nitric oxide donor molsidomine for the treatment of schizophrenia.","finding":"","journal":"Medical gas research","studyType":"Clinical Study"}],"tags":[{"label":"molsidomine","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Estrogen receptor","category":"target"},{"label":"ESR1","category":"gene"},{"label":"C01DX12","category":"atc"},{"label":"Active","category":"status"},{"label":"Angina pectoris","category":"indication"},{"label":"Cardiovascular Agents","category":"pharmacology"},{"label":"Nitric Oxide Donors","category":"pharmacology"},{"label":"Vasodilator Agents","category":"pharmacology"}],"phase":"phase_2","safety":{"safetySignals":[{"llr":126.157,"date":"","count":51,"signal":"Toxic epidermal necrolysis","source":"DrugCentral FAERS","actionTaken":"Reported 51 times (LLR=126)"},{"llr":82.954,"date":"","count":13,"signal":"Antinuclear antibody negative","source":"DrugCentral FAERS","actionTaken":"Reported 13 times (LLR=83)"},{"llr":80.847,"date":"","count":38,"signal":"Product prescribing error","source":"DrugCentral FAERS","actionTaken":"Reported 38 times (LLR=81)"},{"llr":71.903,"date":"","count":31,"signal":"Electrolyte imbalance","source":"DrugCentral FAERS","actionTaken":"Reported 31 times (LLR=72)"},{"llr":67.833,"date":"","count":69,"signal":"General physical health deterioration","source":"DrugCentral FAERS","actionTaken":"Reported 69 times (LLR=68)"},{"llr":67.37,"date":"","count":16,"signal":"Antiphospholipid syndrome","source":"DrugCentral FAERS","actionTaken":"Reported 16 times (LLR=67)"},{"llr":62.678,"date":"","count":12,"signal":"Herpes simplex reactivation","source":"DrugCentral FAERS","actionTaken":"Reported 12 times (LLR=63)"},{"llr":61.916,"date":"","count":21,"signal":"Dermatitis exfoliative","source":"DrugCentral FAERS","actionTaken":"Reported 21 times (LLR=62)"},{"llr":60.999,"date":"","count":87,"signal":"Fall","source":"DrugCentral FAERS","actionTaken":"Reported 87 times (LLR=61)"},{"llr":59.993,"date":"","count":25,"signal":"Hyperthyroidism","source":"DrugCentral FAERS","actionTaken":"Reported 25 times (LLR=60)"},{"llr":58.335,"date":"","count":13,"signal":"Coombs positive haemolytic anaemia","source":"DrugCentral FAERS","actionTaken":"Reported 13 times (LLR=58)"},{"llr":55.556,"date":"","count":24,"signal":"Cholecystitis","source":"DrugCentral FAERS","actionTaken":"Reported 24 times (LLR=56)"},{"llr":53.921,"date":"","count":14,"signal":"Gastritis haemorrhagic","source":"DrugCentral FAERS","actionTaken":"Reported 14 times (LLR=54)"},{"llr":49.585,"date":"","count":13,"signal":"Complex regional pain syndrome","source":"DrugCentral FAERS","actionTaken":"Reported 13 times (LLR=50)"},{"llr":47.096,"date":"","count":28,"signal":"Respiratory disorder","source":"DrugCentral FAERS","actionTaken":"Reported 28 times (LLR=47)"}],"commonSideEffects":[{"effect":"Toxic epidermal necrolysis","drugRate":"LLR 126","severity":"common"},{"effect":"Antinuclear antibody negative","drugRate":"LLR 83","severity":"common"},{"effect":"Product prescribing error","drugRate":"LLR 81","severity":"common"},{"effect":"Electrolyte imbalance","drugRate":"LLR 72","severity":"common"},{"effect":"General physical health deterioration","drugRate":"LLR 68","severity":"common"},{"effect":"Antiphospholipid syndrome","drugRate":"LLR 67","severity":"common"},{"effect":"Herpes simplex reactivation","drugRate":"LLR 63","severity":"common"},{"effect":"Dermatitis exfoliative","drugRate":"LLR 62","severity":"common"},{"effect":"Fall","drugRate":"LLR 61","severity":"common"},{"effect":"Hyperthyroidism","drugRate":"LLR 60","severity":"common"},{"effect":"Coombs positive haemolytic anaemia","drugRate":"LLR 58","severity":"common"},{"effect":"Cholecystitis","drugRate":"LLR 56","severity":"common"},{"effect":"Gastritis haemorrhagic","drugRate":"LLR 54","severity":"common"},{"effect":"Complex regional pain syndrome","drugRate":"LLR 50","severity":"common"},{"effect":"Respiratory disorder","drugRate":"LLR 47","severity":"common"}]},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"motazomin","offLabel":[],"synonyms":["molsidomine","molsidolat","morsydomine","motazomin","molsidomin"],"timeline":[],"approvals":[],"brandName":"Motazomin","ecosystem":[{"indication":"Angina pectoris","otherDrugs":[{"name":"amlodipine","slug":"amlodipine","company":"Pfizer"},{"name":"atenolol","slug":"atenolol","company":"Alvogen Ipco Sarl"},{"name":"atorvastatin","slug":"atorvastatin","company":"Pfizer"},{"name":"bepridil","slug":"bepridil","company":""}],"globalPrevalence":112000000}],"mechanism":{"target":"Estrogen receptor","targets":[{"gene":"ESR1","source":"DrugCentral","target":"Estrogen receptor","protein":"Estrogen receptor"}],"modality":"Small Molecule","drugClass":"molsidomine","explanation":"Think of it like a traffic jam: when blood vessels are constricted, it's like a traffic jam in your body. Molsidomine helps to 'open up' these blood vessels, allowing blood to flow more easily and reducing the strain on your heart.","oneSentence":"Molsidomine works by releasing nitric oxide, which relaxes blood vessels and improves blood flow to the heart.","technicalDetail":"Molsidomine acts as a prodrug that is metabolized to S-nitroso-N-acetyl-D,L-penicillamine (SAT), which then releases nitric oxide (NO) through a thiol-disulfide exchange reaction, leading to the relaxation of vascular smooth muscle and subsequent vasodilation."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1831","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=MOLSIDOMINE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=MOLSIDOMINE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T12:49:40.987962","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T11:15:39.194316+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"competitors":[{"drugName":"nesiritide","drugSlug":"nesiritide","fdaApproval":"2001-08-10","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"vericiguat","drugSlug":"vericiguat","fdaApproval":"2021-01-19","patentExpiry":"Nov 26, 2032","patentStatus":"Patent protected","relationship":"same-class"}],"genericName":"molsidomine","indications":{"approved":[{"name":"Angina pectoris","source":"DrugCentral","snomedId":194828000,"regulator":"FDA","usPrevalence":null,"globalPrevalence":112000000,"prevalenceMethod":"curated","prevalenceSource":"WHO, 2023"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"nesiritide","brandName":"nesiritide","genericName":"nesiritide","approvalYear":"2001","relationship":"same-class"},{"drugId":"vericiguat","brandName":"vericiguat","genericName":"vericiguat","approvalYear":"2021","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT01363661","phase":"PHASE4","title":"Effect of Molsidomine on the Endothelial (Internal Layer of Blood Vessels) Dysfunction in Patients With Angina Pectoris","status":"COMPLETED","sponsor":"Therabel Pharma SA/NV","startDate":"2011-06","conditions":["Stable Angina Pectoris","Atherosclerosis"],"enrollment":165,"completionDate":"2014-09"},{"nctId":"NCT00382421","phase":"NA","title":"Study to Investigate Effects of Antiischemic Drug Therapy in Silent Ischemia","status":"COMPLETED","sponsor":"Luzerner Kantonsspital","startDate":"1992-02","conditions":["Myocardial Ischemia"],"enrollment":0,"completionDate":"2006-04"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NUI":"N0000167103","NDDF":"005842","UNII":"D46583G77X","CHEBI":"CHEBI:31861","INN_ID":"3125","RXNORM":"7023","UMLSCUI":"C0026400","ChEMBL_ID":"CHEMBL1329455","KEGG_DRUG":"D01320","DRUGBANK_ID":"DB09282","PUBCHEM_CID":"5353788","SNOMEDCT_US":"698196008","MESH_DESCRIPTOR_UI":"D008981"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"pharmacokinetics":{"source":"DrugCentral","halfLife":"1.6 hours","clearance":"11.0 mL/min/kg","bioavailability":"48%","fractionUnbound":"1.0%","volumeOfDistribution":"1.4 L/kg"},"publicationCount":758,"therapeuticAreas":["Cardiovascular"],"atcClassification":{"source":"DrugCentral","atcCode":"C01DX12","allCodes":["C01DX12"]},"biosimilarFilings":[],"recentPublications":[{"date":"2026 Jan 2","pmid":"41480767","title":"Nitric oxide required for transition to slower hepatic protein synthesis rates during long-term caloric restriction.","journal":"The Journal of clinical investigation"},{"date":"2026","pmid":"41273551","title":"Exploring Therapeutic and Multitarget Mechanism of Molsidomine on Cerebral Ischemia: Molecular Docking and Multifaceted In Silico Study.","journal":"Advances in experimental medicine and biology"},{"date":"2025 Sep 5","pmid":"40490173","title":"Molsidomine ameliorates DEXA-induced insulin resistance: Involvement of HMGB1/JAK1/STAT3 signaling pathway.","journal":"European journal of pharmacology"},{"date":"2025 Jun","pmid":"40453484","title":"Comparative analysis of two standardised protocols for prevention of vasospasm following aneurysmal subarachnoid haemorrhage: A retrospective pilot study.","journal":"European journal of anaesthesiology and intensive care"},{"date":"2025 Sep 1","pmid":"40251020","title":"Corrigendum: Evaluation of the potential efficacy of the nitric oxide donor molsidomine for the treatment of schizophrenia.","journal":"Medical gas research"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Motazomin is a small molecule with the CAS number 276. It is also known by the synonyms CAS 276, CAS-276, CAS276, CORVASAL, CORVATON MITE, and CORVATON RET.","enrichmentLevel":5,"visitCount":0,"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T11:15:39.194316+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}